|
Post by peppy on Nov 23, 2015 6:15:46 GMT -5
I angry with Sanofi, I feel like a puppet on a string. Repeating myself, if I now finally know that Afrezza is priced to fail, so does the board of directors. The goal of the board is to see afrezza succeed. The goal of the board is that Mannkind succeed, and what mankind has is technosphere, afrezza, patents and debt. If is clear to me the plan has to change;It is then also clear to the board of directors. What the heck-o-le is the plan? I have seen threads, short interest, bankruptcy, ...blah, blah, blah. The thread we need is what is the success plan?
So diabetics do not get anymore choices because it is inconvenient to other profit centers? screencast.com/t/lfvJnQwPlF5H
Afrezza gets snuck ..... status quo? screencast.com/t/XjI1oA2v5
When I see Endo's interviewed regarding Afrezza, I swear I see them stiffen up, and take on a posture... hmmmm These endo's are not stupid. They act like they are afraid on the delivery system to the lung. They are fine with delivery systems that take out the liver or kidney? screencast.com/t/gOZ7T3KnLgH
The plan was to get people on afrezza, they will like it so much, they will spread the word. So sanofi priced it like a Rolls Royce. We know they are out there, but when was the last time you saw one go down the road. screencast.com/t/SGh9fJcmjF
|
|
|
Post by oldfishtowner on Nov 23, 2015 8:23:36 GMT -5
Roughly, yes. I mentioned in a previous post up above how comparison is made difficult by afrezza being dosed in cartridges plus the reports of higher dosages being required to match the diabetic's previous dose of lispro as well as the sometimes required additional dose 1-2 hours after a meal in order to cope with late digesting carbs. One frustrating thing is that no one is reporting their actual cartridge usage -- i.e. keeping track of what they started with and how it is changing. Consequently, there's no way to estimate the average cartridge consumption, and that will be an important factor in how insurance companies make their decision. It looks like it depends on the insurance plan. The caremark cost estimator gives a very different picture for Afrezza under the federal NALC plans (one of the postal service employees plans) listed on opm's open season website: www.caremark.com/wps/myportal/FRAMED_CHECK_DRUG_COST [NOTE: This link doesn't work directly unless you have an account - requires log on. To get to the calculator you have to go through opm.gov/openseason, follow the plan information link and go to the NALC plan website, then follow a series of menus to the cost estimator (caremark) site: choose High Option Plan, Plans and Benefits, RX Drug Benefits, Prescription Cost Calculator. Likely the cookies needed to avoid log-ons are picked up along the way.] Try the different doses of Afrezza listed. And you can compare with other insulins as well. The coverage seems to be too good to be true. I almost have to believe there is an error in the calculator. The calculator shows an annual cost of $324.44 ($80 for each 90-day supply of 270 4-unit cartridges, using 60-cartridge packs). Note that the 60-cartridge packs are less expensive than the 30-cartridge packs. Afrezza is still more expensive than Novolog, but is very affordable. Maybe this is an error, but maybe insurance coverage is starting to significantly improve.
|
|
|
Post by dreamboatcruise on Nov 23, 2015 10:52:18 GMT -5
peppy... seems like we are missing crucial insight into how negotiations with formularies occur at present. It certainly has become harder to get good formulary placement than it was a decade ago... or even 5 years ago. I've asked these questions before with no one offering any info... what type of exclusivity deals are done for prandials like Novolog and Humalog, how long do they last and would they likely be blocking Afrezza? So if we were going to be coming up with a plan, I'd say the first thing we need to do is hire an expert in PBM Access. I'm assuming SNY has one, though obviously if they don't, hiring one should be top of the todo list (sarcasm... since we know they do have these people).
|
|
|
Post by rrtzmd on Nov 23, 2015 11:26:14 GMT -5
Roughly, yes. I mentioned in a previous post up above how comparison is made difficult by afrezza being dosed in cartridges plus the reports of higher dosages being required to match the diabetic's previous dose of lispro as well as the sometimes required additional dose 1-2 hours after a meal in order to cope with late digesting carbs. One frustrating thing is that no one is reporting their actual cartridge usage -- i.e. keeping track of what they started with and how it is changing. Consequently, there's no way to estimate the average cartridge consumption, and that will be an important factor in how insurance companies make their decision. It looks like it depends on the insurance plan. The caremark cost estimator gives a very different picture for Afrezza under the federal NALC plans (one of the postal service employees plans) listed on opm's open season website: www.caremark.com/wps/myportal/FRAMED_CHECK_DRUG_COST [NOTE: This link doesn't work directly unless you have an account - requires log on. To get to the calculator you have to go through opm.gov/openseason, follow the plan information link and go to the NALC plan website, then follow a series of menus to the cost estimator (caremark) site: choose High Option Plan, Plans and Benefits, RX Drug Benefits, Prescription Cost Calculator. Likely the cookies needed to avoid log-ons are picked up along the way.] Try the different doses of Afrezza listed. And you can compare with other insulins as well. The coverage seems to be too good to be true. I almost have to believe there is an error in the calculator. The calculator shows an annual cost of $324.44 ($80 for each 90-day supply of 270 4-unit cartridges, using 60-cartridge packs). Note that the 60-cartridge packs are less expensive than the 30-cartridge packs. Afrezza is still more expensive than Novolog, but is very affordable. Maybe this is an error, but maybe insurance coverage is starting to significantly improve. Easier to reach via: NALC benefitsThen click on "prescription cost calculator" at the top of the page. The numbers they provide don't quite make sense. Afrezza annual cost for the employee: mail order = $324, retail pharmacy = $1253. But then it says employer's cost: mail order = $2384, retail pharmacy = $1532. Why the reversal? It seems like the retail should be higher either way. In any case, it points out the leverage large groups can have in getting improved benefits.
|
|
|
Post by compound26 on Nov 23, 2015 13:08:43 GMT -5
|
|